pimavanserin
Antipsychotic • Brands: Nuplazid
Last reviewed: 2025-12-30
General information
- Class: Antipsychotic
- Common US brands: Nuplazid
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Selective serotonin 5-HT2A inverse agonist/antagonist with minimal dopamine receptor activity. Approved for hallucinations and delusions associated with Parkinson’s disease psychosis (label).
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP3A5, CYP2J2 (minor), CYP2D6 (minor)
- Half‑life: Single-dose mean 57 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- NUPLAZID (pimavanserin tartrate) prescribing information — DailyMed (2025)
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial — Lancet (2014)
- Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis — The Annals of Pharmacotherapy (2017)
- Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus — CNS Spectrums (2018)